Literature DB >> 28331481

Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease.

Seymour Katz1.   

Abstract

Leukocytapheresis has reemerged as a novel "nondrug" approach in the treatment of inflammatory bowel disease. The technique involves the extracorporeal passage of peripheral blood through a column of cellulose diacetate beads (Adacolumn) or a nonwoven polyester fiber filter (Cellsorba). The benefits accrued from the filtered extraction of granulocytes, monocytes (Adacolumn), and lymphocytes (Cellsorba) appear greater than the simple extraction of these cells. There appears to be an immunologic modulation of leukocytes and dendritic cells and a diminished response to proinflammatory cytokines. Unfortunately, blinded placebo-controlled trials are lacking. Nevertheless, the aggregate clinical experience detailed in this review suggests a relatively safe and attractive alternative to current inflammatory bowel disease therapies. Randomized, controlled sham trials are in progress.

Entities:  

Keywords:  Leukocytapheresis; granulocytes; inflammatory cytokines; monocytes

Year:  2006        PMID: 28331481      PMCID: PMC5359938     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  59 in total

1.  Therapeutic cytapheresis for inflammatory bowel disease.

Authors:  K Sawada; T Shimoyama
Journal:  Ther Apher       Date:  1998-05

2.  Granulocyte apheresis in inflammatory bowel disease: possible mechanisms of effect.

Authors:  B J Rembacken; H E Newbould; S J Richards; S A Misbah; M E Dixon; D M Chalmers; A T Axon
Journal:  Ther Apher       Date:  1998-05

Review 3.  Leukocytapheresis using a leukocyte removal filter.

Authors:  Junichi Shirokaze
Journal:  Ther Apher       Date:  2002-08

4.  Enhanced mucosal cytokine production in inflammatory bowel disease.

Authors:  W E Pullman; S Elsbury; M Kobayashi; A J Hapel; W F Doe
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

5.  Why is leukocytapheresis effective in inflammatory bowel diseases?

Authors:  Yutaka Kohgo
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

6.  Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis.

Authors:  Terasu Honma; Kazuhito Sugimura; Hitoshi Asakura; Jun Matsuzawa; Kohji Suzuki; Masaaki Kobayashi; Yutaka Aoyagi
Journal:  J Clin Gastroenterol       Date:  2005 Nov-Dec       Impact factor: 3.062

7.  Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model.

Authors:  Catherine Van Montfrans; Maria Sol Rodriguez Pena; Inge Pronk; Fiebo J W Ten Kate; Anje A Te Velde; Sander J H Van Deventer
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

8.  Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.

Authors:  Akira Andoh; Atsuhiro Ogawa; Ken-ichi Kitamura; Osamu Inatomi; Sanae Fujino; Tomoyuki Tsujikawa; Masaya Sasaki; Keiichi Mitsuyama; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

9.  Granulocytapheresis as a possible cancer treatment.

Authors:  T Tabuchi; H Ubukata; S Sato; I Nakata; Y Goto; Y Watanabe; T Hashimoto; T Mizuta; M Adachi; T Soma
Journal:  Anticancer Res       Date:  1995 May-Jun       Impact factor: 2.480

10.  Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study.

Authors:  Yasuo Suzuki; Naoki Yoshimura; Abby R Saniabadi; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

View more
  1 in total

Review 1.  Leukocytapheresis in patients with inflammatory bowel diseases.

Authors:  Małgorzata Woźniak; Ilona Kurnatowska; Ewa Małecka-Panas; Renata Talar-Wojnarowska
Journal:  Prz Gastroenterol       Date:  2021-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.